Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects

Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects

Empagliflozin (EMPA), a drug approved for type 2 diabetes management, reduced cardiovascular death but is unknown if it reduces myocardial infarction. We sought to investigate: (i) the effect of EMPA on myocardial function and infarct size after ischemia/reperfusion in mice fed with western diet (WD...

Full description

Bibliographic Details
Main Authors: Ioanna Andreadou, Panagiotis Efentakis, Evangelos Balafas, Gabriele Togliatto, Constantinos H. Davos, Aimilia Varela, Constantinos A. Dimitriou, Panagiota-Efstathia Nikolaou, Eirini Maratou, Vaia Lambadiari, Ignatios Ikonomidis, Nikolaos Kostomitsopoulos, Maria F. Brizzi, George Dimitriadis, Efstathios K. Iliodromitis
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-12-01
Series:Frontiers in Physiology
Subjects:
empagliflozin
cardioprotection
infarct size
cardiac function
molecular signaling
STAT3 pathway
Online Access:http://journal.frontiersin.org/article/10.3389/fphys.2017.01077/full

Similar Items

Similar Items